Fremont, CA (Vocus/PRWEB) March 28, 2011
Optovue Inc., has announced that a study conducted by the University of California at San Diego and published in Optics Express 2009; Vol. 17: 4019-4036, demonstrated that the RTVue fourier/spectral domain OCT was less affected by variability in scan quality, especially low scan quality. Low scan quality can result from patient factors such as cornea opacities, partial cataracts, cloudy vitreous or other factors that diminish the scanning beam signal from and back to the OCT device.
The study authors, Madhusudhanan Balasubramanian, Christopher Bowd, Gianmarco Vizzeri, Robert N. Weinreb, and Linda M. Zangwill, stated: “For RTVue, RNFL thickness measurements in most eyes remained stable across the range of SSQ (changes in RNFL thickness of < 3 microns, however see results from participant H3). These results suggest that, changes in SSQ from best to lowest quality images resulted in minimal, clinically irrelevant, changes in measured RNFL thickness.”
The study scanned eyes with three instruments (RTVue® from Optovue, Inc; Cirrus from Carl Zeiss Meditec; and Spectralis from Heidelberg Engineering) under the following circumstances: 1) best quality, 2) medium quality, 3) poor quality, and 4) with 2 dioptor defocus. All instruments rate image quality based on a numerical scale. This scale was used to determine the 3 different quality levels. Results show the RTVue measurements were least affected by image quality.
In summary, the RTVue changes from the best scans to the worst were less than 3 microns. Spectralis was the most affected by image quality with thickness changes ranging from 20-40 microns from best to worst quality. Cirrus was also affected with a difference of 5-10 microns from best to worst quality. "Image quality and the effects of poor image quality is a very important aspect of imaging that is often overlooked by the clinician. Optovue has worked hard to create robust segmentation algorithms which likely contributed to the reliable results reported in the study, even with poor quality images,” stated Mike Sinai, Ph.D., Sr. Director of Clinical Research for Optovue.
The complete article published in Optics Express can be found by following the link: http://www.opticsinfobase.org/oe/abstract.cfm?uri=oe-17-5-4019
About RTVue® and iVue™
RTVue was the first FDA cleared Fourier domain (also known as spectral domain) OCT launched in the United States, and also the first OCT cleared by the U.S. Food and Drug Administration for both corneal and retinal imaging. The iVue is the compact fourier-domain version of the RTVue OCT, offering the same scanning speed and resolution as the larger system, that includes scanning and reports for retina, retina nerve fiber and cornea assessment by the clinician.
About Optovue® (http://www.optovue.com)
Optovue Inc. is a privately-held ophthalmic device company dedicated to working with eye care professionals and clinical researchers to lead the commercialization of new imaging modalities that improve diagnosis and therapy of ocular disease. Optovue has achieved widespread market success through a combination of unique data analysis design, a reputation for excellent customer service, and rapid innovation of its technology in response to physician feedback. The company is headquartered in Fremont, CA, with operations in Carlsbad, CA and European operations in Heidelberg, Germany.
# # #